William Blair Analysts Decrease Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at William Blair reduced their FY2024 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a note issued to investors on Wednesday, April 17th. William Blair analyst T. Lugo now expects that the biotechnology company will post earnings of $6.66 per share for the year, down from their previous forecast of $6.74. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.14 per share. William Blair also issued estimates for Sarepta Therapeutics’ FY2025 earnings at $14.91 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. The company had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. Sarepta Therapeutics’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.24) EPS.

A number of other analysts also recently issued reports on SRPT. UBS Group lifted their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a report on Friday, March 1st. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Royal Bank of Canada boosted their target price on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Mizuho boosted their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Finally, Evercore ISI boosted their target price on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $158.38.

Sarepta Therapeutics Stock Down 0.8 %

Shares of NASDAQ SRPT opened at $115.62 on Friday. The company has a market capitalization of $10.86 billion, a price-to-earnings ratio of -18.89 and a beta of 0.94. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The business has a 50-day moving average of $126.52 and a two-hundred day moving average of $110.41. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $159.89.

Institutional Trading of Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Mather Group LLC. purchased a new position in Sarepta Therapeutics in the first quarter valued at about $28,000. Montag A & Associates Inc. purchased a new position in Sarepta Therapeutics in the third quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the period. KB Financial Partners LLC purchased a new position in Sarepta Therapeutics in the first quarter valued at about $36,000. Finally, Qube Research & Technologies Ltd purchased a new position in Sarepta Therapeutics in the third quarter valued at about $33,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $123.25, for a total value of $1,848,750.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,815,030. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.